99mtc-3prgd2
Small moleculeexperimentalImaging agent
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2011 (NCT01737112)
Timeline
Indications
Mechanism of action
- Vitronectin receptor alphaINHIBITOR
ITGAV inhibitor
Chemistry & pharmacology
- Imaging
- 99-technetium
Oral
No
Parenteral
No
Topical
No
Also known as
- 99mtc-3prgd2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04233476 | Phase 3 | Oct 12, 2019 | Chinese Academy of Medical Sciences, Genesis Pharmaceuticals, RDO Pharm. |
| NCT03974685 | Phase 1 | Dec 12, 2018 | Chinese Academy of Medical Sciences, MedAlly Solutions Co., Ltd., RDO Pharm. |
| NCT02742168 | Early Phase 1 (Phase 1) | Jan 1, 2016 | Fujian Medical University |
| NCT02723760 | Early Phase 1 (Phase 1) | Nov 1, 2015 | Fujian Medical University |
| NCT02744729 | Early Phase 1 (Phase 1) | Oct 1, 2015 | Fujian Medical University |
| NCT01737112 | Early Phase 1 (Phase 1) | Feb 1, 2011 | Tsinghua University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fujian Medical University | Academic/Hospital | 3 | 3 | 1 | 2015 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 2 | 2018 |
| RDO Pharm. | Government | 2 | 2 | 2 | 2018 |
| Genesis Pharmaceuticals | For profit | 1 | 0 | 1 | 2019 |
| MedAlly Solutions Co., Ltd. | For profit | 1 | 0 | 1 | 2018 |
| Tsinghua University | Academic/Hospital | 1 | 1 | 1 | 2011 |
6 organizations
Page 1 / 1